Retinal surface macrophages play key roles in the regulation of immune response, maintenance of vitreous clarity, and tissue repair. We examined the variation of parafoveal surface macrophages in a thyroid eye disease (TED) patient before and after treatment with teprotumumab (Tepezza, Horizon therapeutics). Pre- and posttreatment parafoveal surface macrophages were imaged using clinical en face OCT, and their density was assessed using a novel cell density mapping technique. Pretreatment, surface macrophage cell density was high. Macrophages had a nonuniform spatial distribution, and their appearance was round with few protrusions, consistent with an “activated” state. Posttreatment, cell density decreased. The macrophages were regularly spaced and had a ramified appearance and filopodia-like processes, consistent with a “quiescent” state. Surface macrophage density decreased as the Clinical Activity Score (CAS) decreased with teprotumumab treatment, suggesting a potential association of these cells with an underlying intraocular and retinal inflammatory process previously not described in TED.
CITATION STYLE
Otero-Marquez, O., Fayad, M., Pinhas, A., Chui, T. Y. P., Rosen, R. B., & Reddy, H. S. (2022). Retinal Surface Macrophage Changes in Thyroid Eye Disease before and after Treatment with Teprotumumab. Case Reports in Ophthalmological Medicine, 2022, 1–5. https://doi.org/10.1155/2022/5275309
Mendeley helps you to discover research relevant for your work.